This tragic story of a 62 year old man who died waiting for critical surgery is used to show the structural problems within our health care system. Dr. David Zitner explains that such problems mean we all have to be much more involved in our health care. The story and article brought regional and national attention to the problem.
The Canadian Health Care Consensus Group explains the miscalculations used by the uninformed in the health care reform debate; AIMS tells a House Committee that bad policy is killing jobs and shows a Senate Committee the true weight of equalization. And meet the new wonks.
The public-private debate is undermined by a misuse of health care data.
The public-private health care debate can seem a lot like a high school math class – there's a lot of noise, a few troublemakers and frequently a profound misunderstanding of the numbers. The Canadian Health Care Consensus Group (CHCCG), coordinated by AIMS, is adding a little clarity to the debate. This third paper published by the CHCCG shows how the data is often misunderstood and misused.
Increasing pharmaceutical spending can decrease health care costs.
It’s a common cry – the increasing cost of prescription drugs is bankrupting the health care system. But is that actually the case? Advancements in technology have dramatically changed the face of medical care, and pharmaceuticals have been in the forefront. This paper published with the Canadian Health Care Consensus Group examines how today's drugs actually save the system money.
From the fishery - to education - to pharmacare policy, this edition of The Beacon examines public policy for a number of issues.
It is considered one of the most pressing issues in health care in Canada, the catastrophic gap in prescription drug coverage. On 16 May 2006, AIMS gathered the leading experts from across the country to discuss the topic. This is a summary of the "When Tea and Sympathy are not Enough" conference.
In this op/ed in The New York Post, AIMS president Brian Lee Crowley explains the real reason why brand-name drugs cost less in Canada. In reply to an ad campaign by the American Association of Retired Persons (AARP) urging Congress to legalize the importation of prescription drugs from Canada, Crowley explains the reason isn't simply price controls. And he tells Americans to be very careful what they wish for.
From the war in Afghanistan, to the future of Health Care in Canada, to the role of public policy think tanks - this Beacon provides insight on some of the major policy issues facing the region and the country.